|Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes
|Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases
|Research and practice in thrombosis and haemostasis
|Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery-a systematic review
|Journal of thoracic disease
|Intravenous thrombolysis after dabigatran reversal by idarucizumab: a systematic review of the literature.
|Frontiers in Neurology
|Use of direct-acting oral anticoagulants in solid organ transplantation: a systematic review.
|Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants
|Journal of the American College of Cardiology
|Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
|Frontiers in neurology
|Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.
|The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis
|Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: a systematic review of the literature.
|Clinical Neurology and Neurosurgery
|Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review
|Journal of neurology, neurosurgery, and psychiatry
|The reversal of bleeding caused by new oral anticoagulants (NOACs): a systematic review and meta-analysis.
|Clinical and Applied Thrombosis/Hemostasis
|Idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.
|American Journal of Therapeutics
|Current evidence of oral anticoagulant reversal: A systematic review
|Anticoagulation reversal in vitamin K antagonist-associated intracerebral hemorrhage: a systematic review
|Journal of thrombosis and thrombolysis